GEO series
Molecular Pathogenesis of Alzheimer's Disease Onset in a Mouse Model: Effects of Cannabidiol Treatment
GSE304212
Mus musculus (mouse)
RNA-seq (gene expression)
60 samples
Submitted 2025/08/18
Platform GPL34290
At a glance
RNA-seq (gene expression) · mouse · 60 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Mus musculus (mouse)
- Samples
- 60 samples: 60 samples, each with a distinct title — no replicated groupsGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Molecular pathogenesis of Alzheimer's disease onset in a mouse model: effects of cannabidiol treatmentFrontiers in neuroscience · 2025
Summary (written by the submitters)
Alzheimer’s disease (AD) is a common neurodegenerative condition involving a complex blend of disturbances in synaptic development and maintenance, neurovascular cross-talk, ionic and nutrient transport, and mitochondrial metabolism. The precise molecular profile of AD onset with insight for major pathological contributors remains unclear with corresponding impedances in therapeutic development.
Read the full summary ↓
The current study sought two objectives, as (i) to resolve the molecular pathogenesis from cognitive impairment to the onset of AD-like neuropathology and (ii) whether the novel agent cannabidiol (CBD), noted for its neuroprotective effects, influences the molecular transition associated with AD onset. Dietary CBD was administered daily (80-100 mg/kg/day) in male 3xTg-AD mice and wild-type B6129SF2/J animals from 4.5 to 6.5 mo of age with inclusion of vehicle controls. RNA sequencing encompassed longitudinal and cross-sectional blood and brain samples respectively. Metabolomics and behavioral analyses examined brain regions (cortex, hippocampus) and associated integrated neurocircuitry. There were >1,000 differentially expressed markers of AD onset, whereby >75% were either eliminated or reversed in the direction of expression in response to CBD. Signaling pathways encompassed synaptic development and plasticity (e.g., Foxp2), neurovascular interactions (Smad9, Angptl6), receptors and ion channels (Gria4, Chrna2, Rgs7/Rgs7bp), mitochondrial genes (Ndufa7, Cox7a2), immunity (Ncr1), oxidation-reduction (Esr1), lipid synthesis (Fasn, ApoE), and carbohydrate metabolism (Mafa, Mlxipl). As potentially addressable with CBD treatment, AD onset represents molecular integration of neurovascular interactions, channelopathies, metabolic disturbances, and aberrations in developmental genes with involvement of major pathological contributors such as inflammation, oxidative signaling, dyslipidemia, and insulin resistance.
Published in
Bishara MA, Chum PP, Miot FEL et al.
· Frontiers in neuroscience 2025
· PMID 40979532
· doi:10.3389/fnins.2025.1667585
This dataset
Download · which file do I need?
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
1 · Just have a look
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
2 · Re-analyse it
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE304212_RAW.tar (it can run to tens of gigabytes).
3 · Start from the raw reads
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1299390 and SRA study SRP605487. Searching any of these in the dataset finder brings you back here.
Study design
60 samples, each with a distinct title — no replicated groups
Any grouping that defines a comparison lives in the sample characteristics, which GEO records separately from the titles.
How we read this: Read from 60 sample titles: 60 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
Samples in this study
- GSM9145194 tb_5442_B6129SF2/J, CBD treatment group, week 0, age 4.5 mo, male
- GSM9145195 tb_5444_B6129SF2/J, CBD treatment group, week 0, age 4.5 mo, male
- GSM9145196 tb_5445_B6129SF2/J, CBD treatment group, week 0, age 4.5 mo, male
- GSM9145197 tb_5448_B6129SF2/J, CBD treatment group, week 0, age 4.5 mo, male
- GSM9145198 tb_5449_B6129SF2/J, CBD treatment group, week 0, age 4.5 mo, male
- GSM9145199 tb_5441_B6129SF2/J, vehicle group, week 0, age 4.5 mo, male
- GSM9145200 tb_5443_B6129SF2/J, vehicle group, week 0, age 4.5 mo, male
- GSM9145201 tb_5447_B6129SF2/J, vehicle group, week 0, age 4.5 mo, male
- GSM9145202 tb_5446_B6129SF2/J, untreated, week 0, age 4.5 mo, male
- GSM9145203 tb_5450_B6129SF2/J, untreated, week 0, age 4.5 mo, male
- GSM9145204 tb_5551_3xTg-AD, CBD treatment group, week 0, age 4.5 mo, male
- GSM9145205 tb_5553_3xTg-AD, CBD treatment group, week 0, age 4.5 mo, male
- GSM9145206 tb_5555_3xTg-AD, CBD treatment group, week 0, age 4.5 mo, male
- GSM9145207 tb_5547_3xTg-AD, CBD treatment group, week 0, age 4.5 mo, male
- GSM9145208 tb_5549_3xTg-AD, CBD treatment group, week 0, age 4.5 mo, male
- GSM9145209 tb_5550_3xTg-AD, vehicle group, week 0, age 4.5 mo, male
- GSM9145210 tb_5552_3xTg-AD, vehicle group, week 0, age 4.5 mo, male
- GSM9145211 tb_5554_3xTg-AD, vehicle group, week 0, age 4.5 mo, male
- GSM9145212 tb_5546_3xTg-AD, vehicle group, week 0, age 4.5 mo, male
- GSM9145213 tb_5548_3xTg-AD, vehicle group, week 0, age 4.5 mo, male
- GSM9145214 wb_5442_B6129SF2/J, CBD treatment group, week 8, age 6.5 mo, male
- GSM9145215 wb_5444_B6129SF2/J, CBD treatment group, week 8, age 6.5 mo, male
- GSM9145216 wb_5445_B6129SF2/J, CBD treatment group, week 8, age 6.5 mo, male
- GSM9145217 wb_5448_B6129SF2/J, CBD treatment group, week 8, age 6.5 mo, male
- GSM9145218 wb_5449_B6129SF2/J, CBD treatment group, week 8, age 6.5 mo, male
- GSM9145219 wb_5441_B6129SF2/J, vehicle group, week 8, age 6.5 mo, male
- GSM9145220 wb_5443_B6129SF2/J, vehicle group, week 8, age 6.5 mo, male
- GSM9145221 wb_5447_B6129SF2/J, vehicle group, week 8, age 6.5 mo, male
- GSM9145222 wb_5446_B6129SF2/J, untreated, week 8, age 6.5 mo, male
- GSM9145223 wb_5450_B6129SF2/J, untreated, week 8, age 6.5 mo, male
- GSM9145224 wb_5551_3xTg-AD, CBD treatment group, week 8, age 6.5 mo, male
- GSM9145225 wb_5553_3xTg-AD, CBD treatment group, week 8, age 6.5 mo, male
- GSM9145226 wb_5555_3xTg-AD, CBD treatment group, week 8, age 6.5 mo, male
- GSM9145227 wb_5547_3xTg-AD, CBD treatment group, week 8, age 6.5 mo, male
- GSM9145228 wb_5549_3xTg-AD, CBD treatment group, week 8, age 6.5 mo, male
- GSM9145229 wb_5550_3xTg-AD, vehicle group, week 8, age 6.5 mo, male
- GSM9145230 wb_5552_3xTg-AD, vehicle group, week 8, age 6.5 mo, male
- GSM9145231 wb_5554_3xTg-AD, vehicle group, week 8, age 6.5 mo, male
- GSM9145232 wb_5546_3xTg-AD, vehicle group, week 8, age 6.5 mo, male
- GSM9145233 wb_5548_3xTg-AD, vehicle group, week 8, age 6.5 mo, male
+ 20 more — browse all 60 samples with per-sample file links →
Datasets on a similar topic
- GSE327604 Epigenetic control of microglial mitochondrial immunity by KAT7 drives Alzheimer’s disease pathogenesis [RNA-Seq] 12 samples shares pathogenesis, alzheimer
- GSE253570 Molecular signatures and spatial distribution of disease-associated cellular populations in early-onset Alzheimer's disease mouse brain 12 samples shares alzheimer, onset
- GSE176506 Synergistic behavioral and neuroinflammatory effects of amyloid neuropathology and sepsis survival in a murine model of Alzheimer’s disease 112 samples shares alzheimer
- GSE302153 Study of Molecular and Transcriptomic Age-related Changes in the Dorsal and Ventral Areas of Hippocampus in the 5xFAD Mouse Model of Alzheimer’s Disease 32 samples shares alzheimer
- GSE98969 Single cell RNA-seq identifies a unique microglia type associated with Alzheimer’s disease [RNA] 97 samples shares alzheimer
- GSE261670 ASOs are an effective treatment for disease-associated oligodendrocyte signatures in premanifest and symptomatic SCA3 mice 74 samples shares treatment
- GSE223424 Immune checkpoint TIM-3 regulates microglia and Alzheimer’s disease 57 samples shares alzheimer
- GSE273690 Adhesion G protein-coupled receptor ADGRG1 promotes protective microglial response in Alzheimer’s disease 48 samples shares alzheimer
Share this dataset
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.